Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients
A Phase IV Multicenter Trial to Evaluate Real-world Health Outcomes and Economic Impact of Panitumumab Versus Standard-of-care in the Treatment of Patients With Chemotherapy-refractory Metastatic Colorectal Cancer
This is a phase IV multicenter trial to evaluate real-world health outcomes and economic impact of panitumumab versus standard-of-care (SOC) in the treatment of patients with chemotherapy-refractory metastatic colorectal cancer (mCRC).
The study will enable real-life health economics and outcome research (HEOR) to assess the impact of panitumumab in the Quebec population.
The primary objective is to evaluate real-world health outcomes and economic impact of panitumumab in the treatment of patients with chemotherapy-refractory mCRC in comparison with SOC. The secondary objectives are to confirm survival data, to assess the quality of life of patients and to assess the health care resource utilization of patients.
Patients with a mutated KRAS gene will be treated with standard-of-care (SOC) and patients with a non-mutated (wild type) KRAS gene will be treated with panitumumab.
During the course of the study, data will be collected on quality of life and work productivity. Patients will be asked to fill a set of questionnaires at their recruitment in the study and at every 3 months after treatment initiation.
研究概览
地位
条件
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Québec、加拿大、G1R 2J6
- Centre Hospitalier Universitaire de Québec (CHU, Hôtel-Dieu de Québec)
-
-
Quebec
-
Lévis、Quebec、加拿大、G6V 3Z1
- CSSS Alphonse-Desjardins (CHAU, Hôtel-Dieu de Lévis)
-
Montréal、Quebec、加拿大、H2X 3J4
- Centre hospitalier de l'Université de Montréal (CHUM)
-
Montréal、Quebec、加拿大、H1T 2M4
- CIUSSS de l'Est-de-l'Île-de-Montréal (Hôpital Maisonneuve-Rosemont)
-
Sherbrooke、Quebec、加拿大、J1H 5N4
- Centre hospitalier universitaire de Sherbrooke (CHUS)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients with a histologically confirmed diagnosis of mCRC.
- Immunohistochemical evidence of EGFR expression.
- ECOG performance status of 0, 1 or 2.
- Patients refractory to fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens
- Patients with a wt KRAS scheduled to receive panitumumab as a single agent for the third-line treatment of mCRC or patients with a mt KRAS scheduled to receive SOC for third-line treatment of mCRC.
- Signed and dated IRB-approved informed consent document.
- Ability to read and understand English or French.
- 18 years of age or older.
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting
大体时间:From the date of registration until date of death from any cause, assessed up to 38 months
|
Pharmacoeconomic impact (cost-effectiveness and cost-utility) will be evaluated by questionnaires completed by the patient and caregiver.
These include quality of life, health resource utilization, work productivity and activity impairment, and health questionnaires.
|
From the date of registration until date of death from any cause, assessed up to 38 months
|
合作者和调查者
赞助
调查人员
- 首席研究员:Jean Lachaine, PhD、PeriPharm
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.